Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2024

TCT 416: Impact of Total Stent Length on Long-Term Clinical Outcomes With Newer-Generation Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction: A Subgroup Analysis From the Biostemi ES Randomized Trial

Presenter: Juan F. Iglesias

October 28, 2024

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

Presentation TCT 2022

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

Presenter: Jonas Haener

September 19, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

Advertisement

TCT 416: Impact of Total Stent Length on Long-Term Clinical Outcomes With Newer-Generation Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction: A Subgroup Analysis From the Biostemi ES Randomized Trial

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content